Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Short Interest Update

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 27,159 shares, an increase of 50.6% from the January 15th total of 18,035 shares. Based on an average trading volume of 12,513 shares, the days-to-cover ratio is presently 2.2 days. Based on an average trading volume of 12,513 shares, the days-to-cover ratio is presently 2.2 days.

Algernon Pharmaceuticals Stock Performance

AGNPF opened at $0.04 on Monday. Algernon Pharmaceuticals has a 52 week low of $0.03 and a 52 week high of $0.08. The business has a fifty day simple moving average of $0.05 and a 200-day simple moving average of $0.05.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).